New drug tested for rheumatoid arthritis relief
NCT ID NCT07052032
Summary
This early-stage study is testing a new drug called CND261 in people with rheumatoid arthritis. The main goal is to check if the drug is safe and how it behaves in the body. About 47 participants with moderate to severe arthritis will receive the drug and be monitored for side effects and early signs of effectiveness over one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Candid Clinical Site
RECRUITINGTbilisi, Georgia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGChisinau, Moldova
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGAuckland, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGBucharest, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGCluj-Napoca, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Candid Clinical Site
RECRUITINGKyiv, Ukraine
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.